A Phase 4 interventional study of Diphtheria Antitoxin in Safety Issues, sponsored by PT Bio Farma. Completed at 1 site in Indonesia. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by PT Bio Farma · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to evaluate the safety profile of Diphtheria Antitoxin
To assess the occurrence of serum sickness after Diphtheria Antitoxin administration.
To assess local and systemic reactions within 24 hours to 10 days. To assess the occurrence of positive reactions after the sensitivity test (skin test). To assess the presence of SAE after Diphtheria Antitoxin administration.
PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diphtheria Antitoxin (DAT) Administered intravenously. Dosage: * Mild diphtheria (nose, skin): 20,000 unit * Moderate diphtheria (tonsil - limited): 40,000 - 60,000 unit * Severe diphtheria (more than 1 tonsil, or to the pharyngeal wall, or more than 5 days of illness, or with bull neck): 80,000 - 120,000 unit
Biological: Diphtheria Antitoxin
Dosage form: Solution for injection Dosage: 1. Perform sensitivity tests, and desensitization if necessary. 2. Give the entire treatment dose of antitoxin IV (or IM) in a single administration (except for series of injections needed for desensitization). 3. The recommended DAT treatment dosage ranges (pediatric and adult) are: * Pharyngeal or laryngeal disease of 2 days duration 20,000 - 40,000 unit * Nasopharyngeal disease 40,000 - 60,000 unit * Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck 80,000 - 100,000 unit * Skin lesions only (rare case where treatment is indicated) 20,000 - 40,000 unit
The occurrence of serum sickness after administration of Diphtheria Antitoxin (DAT)
Percentage of serum sickness after administration of Diphtheria Antitoxin (DAT)
Time frame: Within 10 days after injection
The occurrence of local and systemic reactions after administration of Diphtheria Antitoxin (DAT)
Percentage of local and systemic reaction after administration of Diphtheria Antitoxin (DAT)
Time frame: Within 24 hours to 10 days after injection
The occurrence of positive reaction after a sensitivity test (skin test) of Diphtheria Antitoxin (DAT)
Percentage of positive reaction after sensitivity test (skin test) of Diphtheria Antitoxin (DAT)
Time frame: Before injection of Diphtheria Antitoxin
The occurrence of serious adverse event (SAE) after administration of Diphtheria Antitoxin (DAT)
Percentage of serious adverse event (SAE) after administration of Diphtheria Antitoxin (DAT)
Time frame: Within 10 days after injection
Ran from Jan 2023 to primary completion in May 2023, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.